The National Science Foundation-funded effort will address the nationwide shortage of speech-language pathologists, ensure at-risk children receive assistance.
Channavix Therapeutics and Peregrine BioVentures are developing two patent families related to long-lasting, non-opioid, non-addictive pain therapeutics.